Evans Syndrome Treatment & Management
- Author: Prasad Mathew, MBBS, DCH, FAAP; Chief Editor: Hassan M Yaish, MD more...
Management of Evans syndrome is challenging. Although almost all patients require therapy at some time during the course of the disease, the search for a consistent, effective, and nontoxic therapy continues. Medical therapy is the mainstay of management. Response to therapy varies even within the same individual, and the disease is characterized by periods of remission and exacerbation. No randomized trials have been conducted in patients with Evans syndrome, and the evidence for treatment is based on case reports, case series, and retrospective studies.
Patients admitted for severe anemia or thrombocytopenia should have respiratory and cardiovascular functions stabilized first; should receive blood product transfusions, if needed, after consultation with a pediatric hematologist; and should then be started on therapy with steroids or intravenous (IV) immune globulin (IVIg).
A study by Fan et al indicated that while glucocorticoid therapy is effective against AIHA, patients with Evans syndrome require longer treatment than do those with AIHA alone.
In classic cases (ie, presenting with either autoimmune hemolytic anemia [AIHA] or immune thrombocytopenia), bone marrow aspiration is not indicated. When a patient has pancytopenia at presentation or when the diagnosis of immune thrombocytopenia is unconfirmed, bone marrow examination may help exclude an infiltrative pathology or an aplastic marrow. Bone marrow examination may be indicated in unusual cases, in cases refractory to treatment, or in cases when a peripheral blood smear suggests immature myeloid cells.
Additional therapies include splenectomy, alemtuzumab administration, and hematopoietic stem cell transplantation. Autologous and allogeneic stem cell transplantation have been used in a small number of patients (14 patients aged 5-52 years), with mixed results.
Prednisone (eg, 1-2 mg/kg divided 2 or 3 times daily) is the most commonly used first-line agent and often effectively controls acute episodes of Evans syndrome. Although some patients are successfully weaned off steroids, relapses may occur when prednisone is tapered or stopped. Accordingly, an alternate-day steroid regimen is advised, if feasible.
Patients with persistent immune cytopenia and those who require prolonged or high doses of steroids may benefit from IVIg (eg, 1-2 g/kg/day for 1-2 days.[22, 23] Their thrombocytopenia is more likely to respond than their hemolysis is. Long-term control of thrombocytopenia is reportedly achieved with interval doses of IVIg.
Other therapies reported to be effective in small series include the following immunomodulating agents :
In one study, where plasmapheresis was performed in 3 patients, 1 patient had transient responses, at best, to tacrolimus, protein A-Sepharose column plasmapheresis, whole-blood exchange transfusion, and total nodal irradiation. Another patient showed some response to treatment with a combination of Rh D immunoglobulin (anti-D), methotrexate, prednisone, and folic acid (responses to these agents varied).
A newer agent that has been tried in refractory Evans syndrome, with varying results, is rituximab.[25, 26, 27, 28, 29, 30, 31] At present, this agent seems to be used as a second-line therapy. Rituximab is approved for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma. Its binding to cells expressing CD20 results in cell death via a combination of mechanisms (eg, antibody-dependent cell cytotoxicity, complement activation, and apoptosis). Hence, it has been used to treat various autoimmune disorders mediated by autoantibodies.
Galor et al reported the successful use of rituximab in a patient with Evans syndrome. Mantadakis et al reported the successful use of this agent in a patient with long-lasting Evans syndrome refractory to standard treatments; the patient responded well to rituximab and then responded again when relapse occurred 7 months later. In contrast, Grossi et al treated 2 patients with rituximab without success. In fact, the patients had a worsening of their anemia.
Zecca et al described the weekly use of rituximab in 5 children with Evans syndrome, all of whom were successfully treated. In a retrospective review of patients at the Mayo Clinic, Shanafelt reported responses in one, but not both, of the cytopenias among 3 patients with Evans syndrome.
A review by Norton and Roberts of the use of rituximab in 18 patients (age, 0.3-65 years) yielded encouraging results, with sustained complete remission lasting as long as 17 months. In a pediatric prospective series by Rao et al, 2 patients with Evans syndrome were treated with rituximab; 1 had a partial response, and 1 had no response. Complications associated with rituximab in these studies have been minimal; the most common is infusion-associated reaction.
Another agent that has been tried is alemtuzumab, a humanized immunoglobulin G (IgG) monoclonal antibody specific for the CD52 antigen present on T cells and B cells. Willis et al reported on the use of alemtuzumab in 3 patients with Evans syndrome; though a response was seen in 2 patients, both experienced relapses within 3 months.
One pilot study showed that a multiagent approach may be effective in patients with Evans syndrome. Transfusions of red blood cells (RBCs) and platelets were also used as adjuncts to treatment.
In a multicenter study of 156 children with Evans syndrome, Aladjidi et al found that at least one second-line immune treatment (eg, azathioprine, anti-D, cyclosporine, colchicine, hydroxychloroquine, mycophenolate mofetil, rituximab, thrombopoietin-receptor agonists, splenectomy) was needed in 108 cases (69%).
Splenectomy does not have a clearly established role in the treatment of Evans syndrome, but it may be considered in refractory cases. Splenectomy may improve the CBC and reduce steroid dependence; however, relapses are common and, in most cases, occur within 1-2 months after the procedure.
According to a national survey, splenectomy provided a reported duration of response that ranged from 1 week to 5 years; however, the median response duration was just 1 month. The risk of postsplenectomy sepsis appears to be increased in children with Evans syndrome, especially those with pancytopenia.
Diet and Activity
Dietary restrictions are not usually required. Patients receiving steroid therapy should have some restrictions placed on their salt, sugar, and fluid intake to prevent excessive fluid retention.
Activities may have to be restricted to some extent, depending on patient tolerance and the degree of anemia and bruising.
The following consultations may be considered as appropriate:
A patient may be discharged if he or she is clinically stable (eg, if blood counts are rising). Weekly follow-up is recommended with blood counts and physical examinations until counts become stable or return to reference ranges. Subsequent follow-up care may be arranged at intervals of 2-4 weeks. More frequent follow-up care may be indicated for patients with clinical or laboratory signs of recurrence (eg, when steroids are tapered).
Jaime-Perez JC, Guerra-Leal LN, Lopez-Razo ON, Mendez-Ramirez N, Gomez-Almaguer D. Experience with Evans syndrome in an academic referral center. Rev Bras Hematol Hemoter. 2015 Jul-Aug. 37 (4):230-5. [Medline].
Evans RS, Takahashi K, Duane RT. Primary thrombocytopenic purpura and acquired hemolytic anemia. Arch Intern Med. 1951. 87:48-65.
Wang W, Herrod H, Pui CH. Immunoregulatory abnormalities in Evans syndrome. Am J Hematol. 1983 Dec. 15(4):381-90. [Medline].
Wang WC. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol. 1988 Winter. 10(4):330-8. [Medline].
Savasan S, Warrier I, Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child. 1997 Sep. 77(3):245-8. [Medline].
Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005 Mar 15. 105(6):2443-8. [Medline].
Costallat GL, Appenzeller S, Costallat LT. Evans syndrome and Systemic Lupus Erythematosus: Clinical presentation and outcome. Joint Bone Spine. 2011 Sep 22. [Medline].
Franklin VL, Torrance T, Peebles M, Wilkie R, Greene S. Life-threatening autoimmunity with diabetes: management with an insulin pump. Pediatr Diabetes. 2003 Sep. 4(3):151-4. [Medline].
Keung YK, Cobos E, Bolanos-Meade J, et al. Evans syndrome after autologous bone marrow transplant for recurrent Hodgkin's disease. Bone Marrow Transplant. 1997 Dec. 20(12):1099-101. [Medline].
Yarali, Nese; Demirceken, Fulya; Kondolat, Meda; Ozkasap, Serdar; Kara, Abdurrahman; Tunc, et al. A Rare Condition Associated With Celiac Disease: Evans Syndrome. Journal of Pediatric Hematology/Oncology. September 2007. 29 (9):633-635.
Pirofsky B. Immune haemolytic disease: the autoimmune haemolytic anaemias. Clin Haematol. Feb 1975. 4(1):167-89.
Pui CH, Wilimas J, Wang W. Evans syndrome in childhood. J Pediatr. 1980 Nov. 97(5):754-8. [Medline].
Habibi B, Homberg JC, Schaison G, Salmon C. Autoimmune hemolytic anemia in children. A review of 80 cases. Am J Med. 1974 Jan. 56(1):61-9. [Medline].
Ng SC. Evans syndrome: a report on 12 patients. Clin Lab Haematol. 1992. 14(3):189-93. [Medline].
Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol. 1997 Sep-Oct. 19(5):433-7. [Medline].
Genty I, Michel M, Hermine O, Schaeffer A, Godeau B, Rochant H. [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. Rev Med Interne. 2002 Nov. 23(11):901-9. [Medline].
Fagiolo E. Platelet and leukocyte antibodies in autoimmune hemolytic anemia. Acta Haematol. 1976. 56(2):97-106. [Medline].
Kakaiya RM, Sherman LA, Miller WV, Katz AJ. Nature of platelet antibody in Evans syndrome: a case report. Ann Clin Lab Sci. 1981 Nov-Dec. 11(6):511-5. [Medline].
Pegels JG, Helmerhorst FM, van Leeuwen EF. The Evans syndrome: characterization of the responsible autoantibodies. Br J Haematol. 1982 Jul. 51(3):445-50. [Medline].
Fan J, He H, Zhao W, et al. Clinical Features and Treatment Outcomes of Childhood Autoimmune Hemolytic Anemia: A Retrospective Analysis of 68 Cases. J Pediatr Hematol Oncol. 2016 Mar. 38 (2):e50-5. [Medline].
Raetz E, Beatty PG, Adams RH. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Bone Marrow Transplant. 1997 Sep. 20(5):427-9. [Medline].
Blanchette VS, Kirby MA, Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol. 1992 Jul. immunology(3 Suppl 2):72-82. [Medline].
Nuss R, Wang W. Intravenous gamma globulin for thrombocytopenia in children with Evans syndrome. Am J Pediatr Hematol Oncol. 1987 Summer. 9(2):164-7. [Medline].
Janiä D, Krivokapiä-Dokmanoviä L, Jovanoviä N, Laziä J, Rodiä P, Jankoviä S. Glucocorticoid-resistant Evans' syndrome successfully controlled with low-dose cyclosporine. Int J Clin Pharmacol Ther. 2011 Oct. 49(10):622-5. [Medline].
Galor A, O'Brien T. Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome. Int J Hematol. 2003 Nov. 78(4):335-6. [Medline].
Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol. 2004 Nov. 77(3):303-10. [Medline].
Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003 May 15. 101(10):3857-61. [Medline].
Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003 Nov. 78(11):1340-6. [Medline].
Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997 Sep 15. 90(6):2188-95. [Medline].
Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. Jun 14, 2007. [Epub ahead of print]:
Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc. 2010 Jan. 60(1):64-5. [Medline].
Grossi A, Santini V, Longo G, et al. Treatment with anti CD20 antibodies of patients with autoimmune thrombocytopenia with or without hemolytic anemia: worsening in hemoglobin level [abstract]. Blood. 2000. 96:1089A.
Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006. 132:125-137.
Willis F, Marsh JCW, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001. 114:891-898.
Scaradavou A, Bussel J. Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol. 1995 Nov. 17(4):290-5. [Medline].
Aladjidi N, Fernandes H, Leblanc T, et al. Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort. Front Pediatr. 2015. 3:79. [Medline]. [Full Text].